PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

  • PDX Pharmaceuticals Names Greg Goodwin to Board of Directors

    3/31/2020
    read more

  • PDX Pharmaceuticals presented at Biocom’s 10th Annual Global Life Science Partnering Conference

    2/28/2020
    read more

  • PDX Pharmaceuticals raised $4M ($1.5M first milestone payment) in November of 2019 to take its new HER2-targeted therapy to clinical trials.

    1/16/2020
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved